Korro Bio (NASDAQ:KRRO) Rating Reiterated by Royal Bank of Canada

Royal Bank of Canada reaffirmed their outperform rating on shares of Korro Bio (NASDAQ:KRRO) in a research report report published on Thursday, Benzinga reports. They currently have a $95.00 price target on the stock.

A number of other equities analysts also recently issued reports on the stock. William Blair initiated coverage on shares of Korro Bio in a report on Wednesday, August 14th. They set an outperform rating and a $180.00 price objective on the stock. HC Wainwright restated a buy rating and set a $100.00 price target on shares of Korro Bio in a report on Tuesday, September 17th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of Buy and a consensus target price of $135.00.

Korro Bio Trading Down 5.6 %

KRRO stock opened at $36.33 on Thursday. The business has a 50-day simple moving average of $43.48 and a two-hundred day simple moving average of $51.24. Korro Bio has a 52-week low of $9.15 and a 52-week high of $97.91.

Korro Bio (NASDAQ:KRRO) last posted its earnings results on Tuesday, August 13th. The company reported ($2.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.39) by ($0.04). On average, equities research analysts anticipate that Korro Bio will post -10.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Korro Bio

A number of hedge funds have recently made changes to their positions in the business. Atlas Venture Life Science Advisors LLC increased its holdings in Korro Bio by 1.6% during the second quarter. Atlas Venture Life Science Advisors LLC now owns 1,137,149 shares of the company’s stock worth $38,515,000 after buying an additional 17,857 shares during the last quarter. NEA Management Company LLC increased its stake in shares of Korro Bio by 1.7% during the 2nd quarter. NEA Management Company LLC now owns 1,090,793 shares of the company’s stock worth $36,945,000 after purchasing an additional 17,857 shares during the last quarter. Eventide Asset Management LLC bought a new stake in shares of Korro Bio in the 4th quarter worth approximately $26,185,000. Point72 Asset Management L.P. lifted its stake in Korro Bio by 71.6% in the second quarter. Point72 Asset Management L.P. now owns 456,085 shares of the company’s stock valued at $15,448,000 after purchasing an additional 190,259 shares during the last quarter. Finally, 72 Investment Holdings LLC bought a new position in Korro Bio during the fourth quarter valued at $13,269,000. 13.18% of the stock is currently owned by institutional investors.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).